Landscapes / Targets
EGFR exon 20 insertion
3 drugs act on EGFR exon 20 insertion, in 7 active trials · Any stage · updated 20 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs3
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Approved | — | |||
| How it works | Blocks a kinase | ||||
| Also tested for | Non-Small Cell Lung Cancer | ||||
| Open drug page | |||||
EGFR inhibitor (exon 20 insertion mutations) |
Taiho +1 |
Phase 3 | 27 May 2027Phase 3 trial completes | ||
| Next date | 27 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation and 10 more | ||||
| Open drug page | |||||
— |
Phase 2 | Jun 2027Phase 2 trial completes | |||
| Next date | Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 3 of 3 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · openFDA updated 20 Nov 2026